Humacyte

Humacyte is proud to announce that the FDA has granted full approval for Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. This approval is a significant milestone in regenerative medicine,…

Humacyte has just announced that Symvess™  has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, which makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs…

We hope you spoke with our team during this great VAM 2025 conference. We truly appreciate everyone's engagement and interest in Symvess™, our first-in-class, universally implantable, bioengineered human vessel for urgent extremity arterial replacement and repair. With full FDA…

Mohamad A. Hussain, MD, PhD, Vascular and Endovascular Surgeon at Brigham and Women’s Hospital and Assistant Professor of Surgery Harvard Medical School and lead author of the V007 AV access hemodialysis study of Humacyte’s Acellular Tissue Engineered Vessel (ATEV™) presented…

Don’t miss this! Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, Vascular and Endovascular Surgeon at Brigham and Women’s Hospital and Assistant Professor of Surgery Harvard Medical School and lead author of a hemodialysis study of Humacyte’s Acellular Tissue Engineered…

Stop by booth 320 during the upcoming SVS Vascular Annual Meeting on June 4th– 7th. The Humacyte team is ready to let you handle and help you learn more about FDA Approved Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular…

Don’t miss this! VAM 2025 Plenary Session 6 this Friday, June 6th at 10 AM CT Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, Vascular and Endovascular Surgeon at Brigham and Women’s Hospital and Assistant Professor of Surgery Harvard Medical School and lead author of a…

Humacyte has just released first quarter 2025 financial results and provided a business update, highlighting progress made in the U.S. commercial launch and pipeline projects, as well as other corporate initiatives. Key updates include: · The first commercial shipments were made…

😀We hope you had a chance to visit with us during FVS. We truly appreciate everyone's engagement and interest in Symvess™, our first-in-class, universally implantable, bioengineered human vessel for urgent extremity arterial replacement and repair. With our recent FDA…

The Humacyte team is looking forward to the Florida Vascular Society meeting at Conrad Orlando on the 24th-27th! 👋Stop by booth 202 to see and learn more about Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma…

Congratulations to Laura Niklason, M.D., Ph.D., Founder and CEO of Humacyte, for receiving the Triangle Business Journal's Healthcare Leadership Award! Thank you,@TriangleBIZJrnl, for recognizing Laura’s leadership alongside outstanding doctors and healthcare practitioners who…

👋 Thank you @VascularSocal. We hope you had a chance to visit with us during the Southern California Vascular Surgical Society (SCVSS) Annual Meeting this past weekend in San Diego, CA. We truly appreciate everyone's engagement and interest in Symvess™ acellular tissue…

👏 Thank you to the Academy of Managed Care Pharmacy (AMCP 2025) for a great meeting and for the opportunity for our Humacyte team member, Fulton Velez, MD, MS, MBA, Head of Field Value and Market Access, to lead these poster presentations. 🏅 One poster was recognized with a…

🏅 Humacyte is thrilled to announce the first units sold of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma. This marks a pivotal step forward in our mission to enhance patient care. In addition, since our commercial launch a few short weeks…

Dr. Laura Niklason, M.D., Ph.D., President and CEO of Humacyte, Inc., responds to this week's New York Times article. ➡️ Read her statement at the end of the document here: humacyte.gcs-web.com/static-files/9… #Humacyte $HUMA

We hope you had a chance to visit with us or see our presentation during OPMED 2025 in San Antonio, Tx. Thank you to the Defense Strategies Institute for hosting OPMED and to all the Department of Defense (DOD) personnel who participate in the conference. We appreciate your…

The Humacyte team is at OPMED! Stop by booth 302 to see and learn more about Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. With recent FDA Approval and full civilian and military commercial…

Humacyte is proud to announce the publication of our Budget Impact Model (BIM) for the Acellular Tissue Engineered Vessel (ATEV™) in the Journal of Medical Economics. For more details, please read the full press release here: investors.humacyte.com/news-releases/… #Humacyte…